Серлифт

General characteristics. Structure:

Active veshchest: Серлифт 50 mg.
Each coated tablet contains
Sertraline hydrochloride of 50 mg.

Active veshchest: Серлифт 100 mg.
Each coated tablet contains
Sertraline hydrochloride of 100 mg.

Pharmacological properties:

Pharmacodynamics. Sertraline - powerful and selective serotonin reuptake inhibitor (5HT). In clinical doses sertraline blocks serotonin reuptake in thrombocytes of the person.
Sertraline has no affinity to muskarinovy (cholinergic), serotoninovy, dopamine, histamine, benzodiazepine and adrenergic receptors.

Sertraline does not cause medicinal dependence, does not render m-holinoblokiruyushchego and cardiotoxic action. Does not increase activity of a sympathetic nervous system.

Unlike tricyclic antidepressants does not increase body weight.

Pharmacokinetics. Sertraline is slowly adsorbed from digestive tract. Meal has no significant effect on bioavailability of drug. Sertraline is exposed to active metabolism of the first passing through a liver. The main metabolite - N-desmetilsertralin - considerably concedes on activity to sertraline and has practically no antidepressive effect. Equilibrium concentration are reached approximately in a week of treatment (once a day), at the same time double cumulation of drug is observed. Linkng with proteins of plasma makes 98%.

The average elimination half-life of sertraline makes 22-36 hours. Sertraline and N-desmetilsertralin biotransformirutsya actively, the formed metabolites are removed with a stake and with urine in equal quantities. Only 0,2% of sertraline cosecrete kidneys in not changed look. The drug pharmacokinetics at elderly and young patients has no essential differences.

Sertraline gets into breast milk.

There are no data on its ability to pass through a gematoplatsentarny barrier.

Sertraline is not dialyzed.

Indications to use:

• Treatment and prevention of the depressions of different degree of manifestation (from lungs to heavy) including which are followed by feeling of alarm and suitsidoopasny attempts;
• Neurotic, somatoformny depressions;
• Posttraumatic stressful frustration (PTSR);
• Obsessivno-kompulsivnye Frustration (OKF);
• Treatment of the panic frustration which are followed or not followed by an agoraphobia, etc. phobias;
• Treatment of nervous anorexia, bulimia and chronic pain syndromes.

Route of administration and doses:

The standard initial dose of Serlift makes 50 mg irrespective of meal once a day. The initial effect can be shown in 7 days, the full effect of drug is usually shown in 2-4 weeks of treatment. In the absence of effect in several weeks of reception the dose can be gradually increased (by 50 mg a week) to the maximum dose of 200 mg a day in one step.

At prolonged use of Serlift to the patient the minimum effective maintenance dose individually is selected.
Does not demand dose adjustment from elderly patients and patients with somatic burdeness.

Features of use:

Серлифт it is not necessary to appoint together with IMAO, and also within 14 days after the termination of treatment of IMAO. After Serlift's cancellation within 14 days do not appoint IMAO. During treatment by Serlift it is necessary to be careful at control of motor transport and potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Interaction with other medicines:

Cases of serious side effects at the patients receiving sertraline in combination with MAO inhibitors are described. The concomitant use of sertraline with diazepam or Tolbutamidum can lead to change of serumal levels of these drugs.

At simultaneous sertraline reception (200 mg a day) and warfarin perhaps some increase in a prothrombin time. It is necessary to exercise control of this indicator in an initiation of treatment sertraline and after its cancellation. Cimetidinum causes decrease in clearance of sertraline at their combined use.

Sertraline can inhibit metabolism of tricyclic antidepressants therefore it is necessary to be careful at simultaneous use of these drugs.

Contraindications:

• Hypersensitivity to the active agent or other ingredients which are a part of drug
• Combined use of sertraline and MAO inhibitors
• Combined use of sertraline with tryptophane or fenilfluraminy
• Combined use with Pimozidum
• Epilepsy in the period of an aggravation
• Children's age up to 6 years
• Pregnancy and period of a lactation

Pregnancy and lactation

Adequate controlled tests of sertraline at pregnant women and the feeding women were not carried out, Serlift can be appointed in that case when the estimated advantage for mother exceeds possible risk for a fruit and the child.

Overdose:

Heavy symptoms at overdose of sertraline it is not revealed even at purpose of drug in high doses.

Overdose symptoms: the tremor, a disorientation, restlessness, a muscle hyper tone, a hyperreflexia, myoclonic twitchings at first in feet, then extend on all body, spasms in a stomach, a meteorism, diarrhea, nausea, vomiting, dyspepsia.

Overdose treatment: there are no specific antidotes. For reduction of absorption the gastric lavage, use of absorbent carbon is possible. It is necessary to provide normal passability of respiratory tracts, oxygenation and ventilation of the lungs. It is necessary to control functions of vitals, to carry out carrying out a symptomatic and maintenance therapy.

Storage conditions:

To store in the dry place at a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity: 3 years. Not to use after the expiry date specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Tablets of 50 mg and 100 mg.

On 14 pieces in the blister; 2 blisters with the application instruction in a cardboard pack.